ÌÇÐÄvlog

[Skip to Navigation]
Sign In

Distribution of L1 antibodies for human papillomavirus type 8 (HPV-8), HPV-15, and HPV-23 in 46 patients with squamous cell carcinoma, 84 age- and sex-matched control subjects, and 291 healthy blood donors. OD indicates optical density in the enzyme-linked immunosorbent assay reader at 405 nm. P values by analysis of variance between cases and controls were .01 for HPV-8, .09 for HPV-15, and .44 for HPV-23.

Table 1.Ìý
Demographic Characteristics of 46 Case Patients With Cutaneous Squamous Cell Carcinoma and 84 Control Subjects
Table 2.Ìý
Odds Ratios of Squamous Cell Carcinoma by Known and Suspected Risk Factors
Table 3.Ìý
Odds Ratios of Cutaneous Squamous Cell Carcinoma by Serologic Testing for Human Papillomaviruses
1.
Alani ÌýRMMunger ÌýKÌýHuman papillomaviruses and associated malignancies.ÌýÌýJ Clin Oncol. 1998;16330-Ìý337
2.
Not Available,ÌýHuman Papillomaviruses.Ìý Lyon, France International Agency for Research on Cancer1995;IARC Monographs on the Evaluation of Carcinogenic Risks to Humans64
3.
Bosch ÌýFXManos ÌýMMMunoz ÌýN Ìýet al.ÌýÌýPrevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group.ÌýÌýJ Natl Cancer Inst. 1995;87796-Ìý802
4.
zur Hausen ÌýHÌýPapillomavirus infections—a major cause of human cancers.ÌýÌýBiochem Biophys Acta. 1996;1288¹ó55-Ìý¹ó78
5.
Mork ÌýJLie ÌýAKGlattre ÌýE Ìýet al.ÌýÌýHuman papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck.ÌýÌýN Engl J Med. 2001;3441125-Ìý1131
6.
Klussmann ÌýJPWeissenborn ÌýSJWieland ÌýU Ìýet al.ÌýÌýPrevalence, distribution, and viral load of human papillomavirus 16 DNA in tonsillar carcinomas.ÌýÌý°ä²¹²Ô³¦±ð°ù. 2001;922875-Ìý2884
7.
Fuchs ÌýPGPfister ÌýHÌýPapillomaviruses in epidermodysplasia verruciformis.ÌýLacey ÌýCed.ÌýPapillomavirus Reviews: Current Research on Papillomaviruses. Leeds, England Leeds University Press1996;253-Ìý262
8.
de Villiers ÌýELavergne ÌýDMcLaren ÌýKBenton ÌýECÌýPrevailing papillomavirus types in non-melanoma carcinomas of the skin in renal allograft recipients.ÌýÌýInt J Cancer. 1997;73356-Ìý361
9.
Berkhout ÌýRJBouwes Bavinck ÌýJNter Schegget ÌýJÌýPersistence of human papillomavirus DNA in benign and (pre)malignant skin lesions from renal transplant recipients.ÌýÌýJ Clin Microbiol. 2000;382087-Ìý2096
10.
de Jong-Tieben ÌýLMBerkhout ÌýRJter Schegget ÌýJ Ìýet al.ÌýÌýThe prevalence of human papillomavirus DNA in benign keratotic skin lesions of renal transplant recipients with and without a history of skin cancer is equally high.ÌýÌýTransplantation. 2000;6944-Ìý49
11.
Arends ÌýMJBenton ÌýECMcLaren ÌýKMHunter ÌýJAABird ÌýCCÌýRenal allograft recipients with high susceptibility to cutaneous malignancy have an increased prevalence of human papillomavirus DNA in skin tumours and a greater risk of anogenital malignancy.ÌýÌýBr J Cancer. 1997;75722-Ìý728
12.
Burk ÌýRDKadish ÌýASÌýTreasure hunt for human papillomaviruses in nonmelanoma skin cancers.ÌýÌýJ Natl Cancer Inst. 1996;88781-Ìý782
13.
Shamanin ÌýVzur Hausen ÌýHLavergne ÌýD Ìýet al.ÌýÌýHuman papillomavirus infections in nonmelanoma skin cancers from renal transplant recipients and nonimmunosuppressed patients.ÌýÌýJ Natl Cancer Inst. 1996;88802-Ìý811
14.
Pfister ÌýHTer Schegget ÌýJÌýRole of HPV in cutaneous premalignant and malignant tumors.ÌýÌýClin Dermatol. 1997;15335-Ìý347
15.
Harwood ÌýCAMcGregor ÌýJMProby ÌýCMBreuer ÌýJÌýHuman papillomavirus and the development of non-melanoma skin cancer.ÌýÌýJ Clin Pathol. 1999;52249-Ìý253
16.
Boxman ÌýILRussell ÌýAMulder ÌýLHBavinck ÌýJNSchegget ÌýJTGreen ÌýAfor the Nambour Skin Cancer Prevention Study Group,ÌýCase-control study in a subtropical Australian population to assess the relation between non-melanoma skin cancer and epidermodysplasia verruciformis human papillomavirus DNA in plucked eyebrow hairs.ÌýÌýInt J Cancer. 2000;86118-Ìý121
17.
Jackson ÌýSStorey ÌýAÌýE6 proteins from diverse cutaneous HPV types inhibit apoptosis in response to UV damage.ÌýÌýOncogene. 2000;19592-Ìý598
18.
Carter ÌýJJGalloway ÌýDAÌýHumoral immune response to human papillomavirus infection.ÌýÌýClin Dermatol. 1997;15249-Ìý259
19.
Baird ÌýPÌýSerological evidence for the association of papillomavirus and cervical neoplasia.ÌýÌýLancet. 1983;217-Ìý18
20.
Nonnenmacher ÌýBKruger-Kjaer ÌýSSvare ÌýEI Ìýet al.ÌýÌýSeroreactivity to HPV16 virus-like particles as a marker for cervical cancer risk in high-risk populations.ÌýÌýInt J Cancer. 1996;68704-Ìý709
21.
Wideroff ÌýLSchiffman ÌýMHHoover ÌýR Ìýet al.ÌýÌýEpidemiologic determinants of seroreactivity to human papillomavirus (HPV) type 16 virus-like particles in cervical HPV-16 DNA-positive and -negative women.ÌýÌýJ Infect Dis. 1996;174937-Ìý943
22.
Stark ÌýSPetridis ÌýAKGhim ÌýSJ Ìýet al.ÌýÌýPrevalence of antibodies against virus-like particles of epidermodysplasia verruciformis–associated HPV8 in patients at risk of skin cancer.ÌýÌýJ Invest Dermatol. 1998;111696-Ìý701
23.
Bouwes Bavinck ÌýJNStark ÌýSPetridis ÌýAK Ìýet al.ÌýÌýThe presence of antibodies against virus-like particles of epidermodysplasia verruciformis–associated human papillomavirus type 8 in patients with actinic keratoses.ÌýÌýBr J Dermatol. 2000;142103-Ìý109
24.
Wieland ÌýURitzkowsky ÌýAStoltidis ÌýM Ìýet al.ÌýÌýPapillomavirus DNA in basal cell carcinomas of immunocompetent patients.ÌýÌýJ Invest Dermatol. 2000;115124-Ìý128
25.
Kremsdorf ÌýDFavre ÌýMJablonska ÌýS Ìýet al.ÌýÌýMolecular cloning and characterization of the genomes of nine newly recognized human papillomavirus types associated with epidermodysplasia verruciformis.ÌýÌýJ Virol. 1984;521013-Ìý1018
26.
Kozak ÌýMÌýCompilation and analysis of sequences upstream from the translational start site in eukaryotic mRNAs.ÌýÌýNucleic Acids Res. 1984;12857-Ìý872
27.
Norusis ÌýMJÌýSPSS for Windows Professional and Advanced Statistics, Release 8.0.Ìý Chicago, Ill SPSS Inc1998;
28.
Stata Corp,ÌýStata Statistical Software: Release 4.0 for Windows 95.Ìý College Station, Tex Stata Corp1995;
29.
English ÌýDRArmstrong ÌýBKKricker ÌýAÌýReproducibility of reported measurements of sun exposure in a case-control study.ÌýÌýCancer Epidemiol Biomarkers Prev. 1998;7857-Ìý863
30.
Weinstock ÌýMAColditz ÌýGAWillett ÌýWCStampfer ÌýMJRosner ÌýBSpeizer ÌýFEÌýRecall (report) bias and reliability in the retrospective assessment of melanoma risk.ÌýÌýAm J Epidemiol. 1991;133240-Ìý245
31.
Cockburn ÌýMHamilton ÌýAMack ÌýTÌýRecall bias in self-reported melanoma risk factors.ÌýÌýAm J Epidemiol. 2001;1531021-Ìý1026
32.
Silins ÌýIWang ÌýZAvall-Lundqvist ÌýE Ìýet al.ÌýÌýSerological evidence for protection by human papillomavirus (HPV) type 6 infection against HPV type 16 cervical carcinogenesis.ÌýÌýJ Gen Virol. 1999;80 (pt 11) 2931-Ìý2936
33.
Schwartz ÌýSMDaling ÌýJRDoody ÌýDR Ìýet al.ÌýÌýOral cancer risk in relation to sexual history and evidence of human papillomavirus infection.ÌýÌýJ Natl Cancer Inst. 1998;901626-Ìý1636
34.
Favre ÌýMMajewski ÌýSNoszczyk ÌýB Ìýet al.ÌýÌýAntibodies to human papillomavirus type 5 are generated in epidermal repair processes.ÌýÌýJ Invest Dermatol. 2000;114403-Ìý407
35.
Tsambaos ÌýDMonastirli ÌýAKapranos ÌýN Ìýet al.ÌýÌýDetection of human papillomavirus DNA in nongenital seborrhoeic keratoses.ÌýÌýArch Dermatol Res. 1995;287612-Ìý615
36.
Yeatman ÌýJMKilkenny ÌýMMarks ÌýRÌýThe prevalence of seborrhoeic keratoses in an Australian population.ÌýÌýBr J Dermatol. 1997;137411-Ìý414
37.
Sciocchetti ÌýGClemente ÌýGFIngrao ÌýGSacco ÌýFÌýResults of a survey on radioactivity of building materials in Italy.ÌýÌýHealth Phys. 1983;45385-Ìý388
38.
Sperati ÌýAAbeni ÌýDDTagesson ÌýCForastiere ÌýFMiceli ÌýMAxelson ÌýOÌýExposure to indoor background radiation and urinary concentrations of 8-hydroxydeoxyguanosine, a marker of oxidative DNA damage.ÌýÌýEnviron Health Perspect. 1999;107213-Ìý215
39.
Etherington ÌýDJPheby ÌýDFBray ÌýFIÌýAn ecological study of cancer incidence and radon levels in South West England.ÌýÌýEur J Cancer. 1996;32A1189-Ìý1197
40.
Eatough ÌýJPHenshaw ÌýDLÌýThe theoretical risk of non-melanoma skin cancer from environmental radon exposure.ÌýÌýJ Radiol Prot. 1995;1545-Ìý51
Study
JulyÌý2003

Evidence for the Association of Human Papillomavirus Infection and Cutaneous Squamous Cell Carcinoma in Immunocompetent Individuals

Author Affiliations

From the Clinical Epidemiology Unit (Drs Masini, Sera, Picconi, Cattaruzza, and Abeni), Department of Plastic Surgery (Dr Gabrielli), Department of Clinical Dermatology (Drs Melchi and Primavera), and Laboratory (Drs Pirchio and Petasecca), Istituto Dermopatico dell'Immacolata, Rome, Italy; Institut fuer Virologie der Universitaet zu Koeln, Cologne, Germany (Drs Fuchs, Stark, and Pfister and Ms Ploner); and Department of Public Health, Università "La Sapienza," Rome (Dr Cattaruzza). The authors have no relevant financial interest in this article. Dr Fuchs died July 10, 2002.

Arch Dermatol. 2003;139(7):890-894. doi:10.1001/archderm.139.7.890
Abstract

ObjectiveÌý The aim of our study was to evaluate human papillomavirus (HPV) infection as a risk factor for cutaneous squamous cell carcinoma (SCC) in immunocompetent individuals.

DesignÌý Hospital-based case-control study.

SettingÌý Referral center for dermatologic diseases for central and southern Italy.

ParticipantsÌý Consecutive patients with histologically confirmed cutaneous SCC (n = 46) and control subjects (n = 84) chosen by frequency matching (age and sex) among patients admitted with unrelated diseases.

Main Outcome MeasureÌý Infection with epidermodysplasia verruciformis–related HPV types, blindly assessed by serologic testing (viruslike particle enzyme-linked immunosorbent assay). Information was obtained on known potentially confounding risk factors (family history, history and signs of sun exposure, and pigmentary traits) and on history of HPV-related lesions and diseases, assessed by interview and examination by a dermatologist.

ResultsÌý Positive serologic findings for HPV type 8 were associated with SCC (odds ratio, 3.2; 95% confidence interval, 1.3-7.9) independently of other risk factors, whereas positive serologic findings for HPV type 15 were negatively associated with SCC (odds ratio, 0.4; 95% confidence interval, 0.2-0.9). Other variables significantly associated with the tumor were family history of skin cancer, professional or recreational sun exposure, light eye color, high number of solar keratoses and seborrheic keratoses on the body surface, and residency in radon-emitting buildings.

ConclusionsÌý Positive serologic findings for HPV type 8 are associated with SCC occurrence in immunocompetent individuals. Viral infection could act as a cofactor in the tumor development, along with genetic predisposition, solar radiation, and other environmental exposures. If confirmed, these findings could open new perspectives for treatment and prevention of SCC.

HUMAN PAPILLOMAVIRUSES (HPVs) are small DNA viruses that infect epithelial cells and induce a variety of proliferative lesions, such as warts, laryngeal papillomas, and cervical carcinoma.1,2 In addition to their role in anogenital cancer3,4 and probably in squamous cell carcinoma (SCC) of the head and neck,5,6 they are also associated with the development of skin cancer in individuals with epidermodysplasia verruciformis (EV), a rare inherited condition characterized by widespread HPV infection and eventual development of multiple SCCs, predominantly on sun-exposed sites.2

Epidermodysplasia verruciformis–associated and phylogenetically related HPV types (EV-HPV)7 are also frequently found in skin tumors of patients without EV. Immunocompromised individuals, such as organ transplant recipients, seem to be especially prone to HPV infection. They develop numerous skin cancers, primarily SCC on sun-exposed sites, in the years after transplantation.8-10 It has also been shown that allograft recipients with high susceptibility to cutaneous malignancy have an increased prevalence of HPV DNA in skin tumors and a greater risk of anogenital malignancy, probably because of an increased susceptibility to persistent HPV infection due to iatrogenic immunosuppression.11

Despite the mounting body of epidemiologic evidence on the possible role of HPV in cutaneous oncogenesis, studies designed to assess the role of infection with EV-HPV in the development of cutaneous SCC are still rare and conducted mostly on rather small numbers of patients.12-16 Furthermore, as compared with anogenital cancers, there is little information so far on the molecular mechanisms involved in the HPV-dependent skin carcinogenesis.17

As antibodies to HPV capsid antigens are reliable markers of past or present HPV infection,18 and seroepidemiologic methods have been successfully used in studies that linked HPV infections to both anogenital and cutaneous lesions,19-23 we designed this seroepidemiologic study with the aim to evaluate EV-HPV infection as a risk factor for the development of cutaneous SCC in immunocompetent individuals.

Methods
Subjects and study design

This case-control study was conducted in Rome at the Istituto Dermopatico dell'Immacolata, a referral dermatological center for central and southern Italy. The institutional ethical committee approved the study protocol before the study began.

Cases were subjects newly diagnosed as having histologically confirmed cutaneous invasive SCC in one surgical ward from October 1, 1999, to July 31, 2000, who gave their written informed consent to participate in the study. Control subjects were selected among patients with unrelated dermatologic conditions (mostly dermatitis, leg ulcers, alopecia, bullous diseases, and bacterial infections) admitted to 2 medical wards and were frequency matched to the cases by age and sex. Exclusion criteria for cases and controls were the presence of HPV-related skin lesions (warts and condylomas); history of SCC of the mucosae (cervix and head and neck); history or signs and symptoms of immunosuppression (including iatrogenic); and history of skin diseases for which UV radiation therapy was indicated, such as psoriasis or vitiligo, or sun avoidance was recommended, such as connective tissue diseases. Personal history of nonmelanoma skin cancer was an additional exclusion criterion for the controls.

A serum sample was obtained from each study subject, divided into aliquots, and stored at −20°C at Istituto Dermopatico dell'Immacolata until shipped in dry ice by air courier to Cologne, Germany, for testing.

With the use of a standardized questionnaire, detailed information was collected on demographic factors and housing; lifestyle (smoking, sexual habits, and attendance sport facilities such as swimming pools); history of professional and recreational sun exposure; history of sunburns; history of HPV-related skin lesions (warts, condylomas); and personal and family history of any cancer.

A complete skin examination was performed by a dermatologist to assess pigmentary characteristics (ie, eye color), the presence of sunlight-induced skin lesions (ie, solar keratoses, solar lentigines, and solar elastosis), and the number of seborrheic keratoses.

Laboratory methods

The serologic response to the major capsid protein L1 of EV-HPV type 8 (EV-HPV-8), -15, -36, and -23 was tested by enzyme-linked immunosorbent assay with the use of viruslike particles (VLPs). Generation of HPV-8–, HPV-15–, and HPV-36–specific VLPs has been described previously.22,24 In case of HPV-23, the corresponding open reading frame was polymerase chain reaction–amplified by means of cloned reference template25 and primers 5′-TCCTGAGCTCGAGCCACCATGACCCTCTGGCTTCCAGCTTC-3′ (forward) and 5′-GGTCGAGAAGCTTTTATTGGCGACCGATATCGGTTAC-3′ (backward), which build in recognition sites for XhoI and HindIII, respectively. In addition, the translation-initiation signal in the forward primer was artificially optimized according to the data of Kozak.26 The cloning strategy, production, and purification of the VLPs were identical to that described by Wieland and coworkers.24

For each serum sample, the optical density (OD) value of an antigen-free well was subtracted from the mean value of duplicate wells coated with VLPs. A positive serum sample with an OD of 1.0 was included on each plate.

Individual serum samples were scored as antibody positive or negative by using a cutoff OD value based on the distribution of OD values of 291 healthy blood donors, aged 18 to 65 years. After individual values exceeding the mean +3 SD were excluded, the remaining readings were averaged again and the cutoff point was chosen at the 90th percentile of the OD value distribution observed in the healthy donors, to maximize specificity.

Statistical analysis

A power calculation was performed before the study began, and was based on the hypothesis that 20% of the controls and 50% of the cases would have been seropositive for HPV-8. Considering a power of 0.80 and α = .05, a sample composed of 35 cases and 70 controls should have been enrolled.

All statistical analyses were performed with the statistical packages SPSS for Windows, release 8.0,27 and Stata for Windows, release 4.0.28 Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated for known risk factors (family history of skin cancer, light eye color, sunlight-related skin lesions), occupational and recreational sun exposure, history of sunburns, lifestyle-related habits (smoking and housing conditions), serologic findings for EV-HPV, and history of HPV-related diseases.

Unconditional logistic regression models were built to allow for multiple adjusting of confounding and thus to identify variables independently associated with SCC.

In all models, age was considered as a continuous variable. For categorical variables, point estimates were first computed for each category. Adjacent categories for which the calculated ORs were very similar were collapsed in a single category whenever possible, to increase robustness of the estimates. Variables that were measured on a continuous scale were categorized by dichotomizing or dividing in tertiles the distributions of exposed controls, and, where appropriate, adjacent categories were eventually collapsed, as described.

Results

At the end of the study, questionnaires, clinical information, and corresponding serum samples were available for 46 cases and 84 controls. Of 51 clinically eligible case subjects, 2 refused to participate in the study, and in 3 cases the clinical diagnosis was not confirmed by histologic examination. For the enrolled cases, the location of SCC was the lip (n = 13), other regions of the head (n = 27), or other body areas (n = 6). Of 137 eligible controls, 52 refused to participate in the study and 1 was erroneously not requested to donate serum samples.

The demographic characteristics of the study subjects are summarized in Table 1. As expected, cases were mainly elderly men (mean age, 72 years), and no differences in age and sex were observed between cases and controls, indicating that frequency matching on these 2 variables was successful. No differences were observed between cases and controls for place of residency.

The known risk factors for SCC (family history of skin cancer, sun exposure, and light eye color) and sun-induced skin lesions, such as solar keratoses, were strongly associated with disease in our study population (Table 2). The risk of developing SCC was increased also for people with 10 or more seborrheic keratoses on body surfaces and for people who lived in radon-emitting tuff buildings.

Of the 4 EV-HPVs for which antibodies were sought in the serum samples of the study subjects (Table 3), HPV-8 and HPV-36 (members of subgroup A of EV-HPV) were associated with SCC, while HPV-15 and HPV-23 (subgroup B) were not, although the small number of patients positive for HPV-36 and HPV-23 did not allow any inference (Figure 1). Positive serologic findings for HPV-8 were also associated with male sex (OR, 3.3; 95% CI, 1.5-7.5).

In multivariate analysis, positive serologic findings for HPV-8 were confirmed to be associated with SCC, independently of age and sex, other known risk factors (sun exposure [as assessed by profession, history of exposure, and sunburns] and pigmentary traits [as assessed by eye color]), and other variables of interest such as number of seborrheic warts and radon exposure.

Positive serologic findings for HPV-15 were shown to be negatively associated with SCC, and this was confirmed in multivariate analysis.

Comment

The main finding of our study in immunocompetent individuals was that subjects with positive serologic findings for HPV-8 had a 3-fold risk of cutaneous SCC (OR, 3.2; 95% CI, 1.3-7.9), independently of other risk factors. This association is in accordance with previous findings of HPV-specific DNA sequences in tumoral tissue13 and in eyebrow hairs16 of immunocompetent individuals with SCC. Two previous seroepidemiologic studies performed with the same method used in this study showed a high prevalence of antibodies against HPV-8 in patients with SCC (10 positive results in 14 patients compared with about 7% in the general German population)22 and an association of seropositivity for HPV-8 with the development of actinic keratoses (OR, 2.4; 95% CI, 1.1-5.0) and invasive SCC (OR, 2.7; 95% CI, 0.7-11.6) in the population of the tropical island of Saba.23

Our study confirms and strengthens these previous results, as it is based on an adequate sample size and the study participants were recruited in a Mediterranean country (Italy), where genetic and phenotypic characteristics and patterns of solar exposure are quite different from those of previously studied populations.

A possible bias could have been introduced by the high number of potential controls unwilling to participate in the study (52 of 137). However, we carefully matched the cases and controls by age and sex. The controls unwilling to participate were very similar in sex, residency, and skin diseases to those who accepted, but they were significantly older and probably had a lower educational level; this, however, was not associated with HPV-8 infection in the participating controls.

As we expected a high mean age in the study population, pigmentary traits were assessed only by recording eye color, and solar exposure was investigated by simple questions on the lifetime amount of professional or recreational sun exposure (high or low) and history of sunburns, to avoid asking more detailed questions that would have resulted in unreliable information.29-31

By logistic regression, positive serologic findings for HPV-8 were independently associated with SCC occurrence in all models tested, with only slight differences in the point estimates. The adjusted ORs shown in Table 3 are derived from the most parsimonious model, which included only the exposure of interest and the main known risk factors, to minimize inflation of the point estimates and CIs.

Also, for HPV-36, a virus type that belongs to the same subgroup of EV-HPV as HPV-8,9 we observed an adjusted OR of 2.8, suggesting a possible association with SCC. However, because of the low prevalence of HPV-36 in our population, the power of our study (which was calculated on the basis of the expected prevalence of HPV-8) was insufficient to reach statistical significance.

By contrast, seropositivity for HPV-15 was negatively associated with SCC. Our finding that an excess risk was associated only with HPV-8 and possibly with HPV-36, but not with the other EV-HPV types we tested (even if they probably share similar modes of transmission), suggests that the HPV-associated risk is not confounded by differences in lifestyle. Instead, it seems plausible that for cutaneous SCC, like what is known about cervical SCC, high-risk oncogenic HPV types may exist, and also that infection with low-risk HPV types may confer protection against the development of the tumor, probably through immunomediated mechanisms.32

The advantages and limitations of determining HPV infection by detecting antibody response to HPV capsids have been extensively discussed in previous articles by our group22 and others.33 As the VLP–enzyme-linked immunosorbent assay is able to detect present as well as past infections, its validity does not depend on a precise sampling of the tissue, and no obvious cross-reactivity between different HPV types is known, we believed that this method could be particularly useful for the preliminary assessment of cancer risk. Because the viral genome is maintained and expressed in the lesions in most cervical SCC and EV skin cancers, further studies assessing the presence of viral DNA and RNA also in cutaneous SCC in immunocompetent individuals would be needed to prove that HPV-8 may be causally involved in skin malignancy.13 However, we do not know at present whether expression of the viral genome needs to be maintained or is necessary only in the early steps of malignant transformation in cutaneous carcinogenesis.

Moreover, epidermal proliferation limited to small cutaneous areas, such as nonmelanoma skin cancer, was not found sufficient to evoke anti–HPV-5 antibody formation as a marker of process linked to epidermal proliferation, as in conditions implying extensive reepithelization.34 Similarly, it seems difficult to consider HPV-8 antibody formation simply as a marker of process in cutaneous carcinogenesis, especially in immunocompetent individuals.

The presence of 10 or more solar keratoses was strongly associated with the presence of the tumor (OR, 42.8; 95% CI, 5.4-339.2), and all 8 HPV-8–positive subjects with 10 or more solar keratoses had SCC. This result was not surprising, confirming that solar keratoses are to be considered an SCC "in situ," undergoing a long precancerous phase before progressing to invasive carcinoma. However, association between HPV-8 positive serologic findings and presence of 10 or more solar keratoses was not significant (OR, 1.63; 95% CI, 0.57-4.69)

The strong association of seborrheic keratoses with SCC was an unexpected finding. We recorded this variable to verify a reported association with HPV infection35 and sun exposure.36 In fact, the presence and number of seborrheic keratoses was not associated with seropositivity for any of the HPV types tested, while it was associated with increasing age, history of sunburns and number of solar keratoses, family history of skin cancer, and presence of SCC. On the basis of these findings, a high number of seborrheic warts (>10) on the body surface might probably be regarded as a risk marker for SCC occurrence.

Finally, another interesting and unexpected finding was the association between SCC and living in tuff buildings, independently of other risk factors for the tumor and of other socioeconomic indicators (OR, 3.1; 95% CI, 1.2-7.9—adjusted for age, sex, sun exposure, eye color, and HPV-8 serologic findings). Tuff is a building material widely used in central Italy; it originates from volcanic rocks and has a high potential for radon emission.37,38 Although this might be a chance finding, since important cohort studies have not shown excess mortality from skin cancers in underground miners exposed to high radon concentrations, it is possible that environmental radon exposure may interplay with other factors to which miners may be underexposed (eg, solar radiation) in increasing the risk of SCC.39,40

Our study had insufficient power to estimate the possible interactions between different risk factors, and further studies are needed to determine whether a number of "high-risk" cutaneous HPV strains are associated with SCC and how these agents might intervene in the induction of the tumor, most probably acting as a cofactor along with genetic predisposition, solar radiation, and other environmental exposures.

Corresponding author and reprints: Cinzia Masini, MD, Clinical Epidemiology Unit, Istituto Dermopatico dell'Immacolata (IDI-IRCCS), Via Monti di Creta 104, 00167 Rome, Italy (e-mail: c.masini@idi.it).

Accepted for publication November 27, 2002.

This study was supported in part by the "Ricerca Corrente" Program of the Italian Ministry of Health, Rome, 2000. Drs Fuchs and Pfister were supported by a grant from the Center for Molecular Medicine, Cologne University, Cologne.

This study was presented in part as a poster at the World Congress of Dermatology, Paris, France, July 1-5, 2002.

References
1.
Alani ÌýRMMunger ÌýKÌýHuman papillomaviruses and associated malignancies.ÌýÌýJ Clin Oncol. 1998;16330-Ìý337
2.
Not Available,ÌýHuman Papillomaviruses.Ìý Lyon, France International Agency for Research on Cancer1995;IARC Monographs on the Evaluation of Carcinogenic Risks to Humans64
3.
Bosch ÌýFXManos ÌýMMMunoz ÌýN Ìýet al.ÌýÌýPrevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group.ÌýÌýJ Natl Cancer Inst. 1995;87796-Ìý802
4.
zur Hausen ÌýHÌýPapillomavirus infections—a major cause of human cancers.ÌýÌýBiochem Biophys Acta. 1996;1288¹ó55-Ìý¹ó78
5.
Mork ÌýJLie ÌýAKGlattre ÌýE Ìýet al.ÌýÌýHuman papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck.ÌýÌýN Engl J Med. 2001;3441125-Ìý1131
6.
Klussmann ÌýJPWeissenborn ÌýSJWieland ÌýU Ìýet al.ÌýÌýPrevalence, distribution, and viral load of human papillomavirus 16 DNA in tonsillar carcinomas.ÌýÌý°ä²¹²Ô³¦±ð°ù. 2001;922875-Ìý2884
7.
Fuchs ÌýPGPfister ÌýHÌýPapillomaviruses in epidermodysplasia verruciformis.ÌýLacey ÌýCed.ÌýPapillomavirus Reviews: Current Research on Papillomaviruses. Leeds, England Leeds University Press1996;253-Ìý262
8.
de Villiers ÌýELavergne ÌýDMcLaren ÌýKBenton ÌýECÌýPrevailing papillomavirus types in non-melanoma carcinomas of the skin in renal allograft recipients.ÌýÌýInt J Cancer. 1997;73356-Ìý361
9.
Berkhout ÌýRJBouwes Bavinck ÌýJNter Schegget ÌýJÌýPersistence of human papillomavirus DNA in benign and (pre)malignant skin lesions from renal transplant recipients.ÌýÌýJ Clin Microbiol. 2000;382087-Ìý2096
10.
de Jong-Tieben ÌýLMBerkhout ÌýRJter Schegget ÌýJ Ìýet al.ÌýÌýThe prevalence of human papillomavirus DNA in benign keratotic skin lesions of renal transplant recipients with and without a history of skin cancer is equally high.ÌýÌýTransplantation. 2000;6944-Ìý49
11.
Arends ÌýMJBenton ÌýECMcLaren ÌýKMHunter ÌýJAABird ÌýCCÌýRenal allograft recipients with high susceptibility to cutaneous malignancy have an increased prevalence of human papillomavirus DNA in skin tumours and a greater risk of anogenital malignancy.ÌýÌýBr J Cancer. 1997;75722-Ìý728
12.
Burk ÌýRDKadish ÌýASÌýTreasure hunt for human papillomaviruses in nonmelanoma skin cancers.ÌýÌýJ Natl Cancer Inst. 1996;88781-Ìý782
13.
Shamanin ÌýVzur Hausen ÌýHLavergne ÌýD Ìýet al.ÌýÌýHuman papillomavirus infections in nonmelanoma skin cancers from renal transplant recipients and nonimmunosuppressed patients.ÌýÌýJ Natl Cancer Inst. 1996;88802-Ìý811
14.
Pfister ÌýHTer Schegget ÌýJÌýRole of HPV in cutaneous premalignant and malignant tumors.ÌýÌýClin Dermatol. 1997;15335-Ìý347
15.
Harwood ÌýCAMcGregor ÌýJMProby ÌýCMBreuer ÌýJÌýHuman papillomavirus and the development of non-melanoma skin cancer.ÌýÌýJ Clin Pathol. 1999;52249-Ìý253
16.
Boxman ÌýILRussell ÌýAMulder ÌýLHBavinck ÌýJNSchegget ÌýJTGreen ÌýAfor the Nambour Skin Cancer Prevention Study Group,ÌýCase-control study in a subtropical Australian population to assess the relation between non-melanoma skin cancer and epidermodysplasia verruciformis human papillomavirus DNA in plucked eyebrow hairs.ÌýÌýInt J Cancer. 2000;86118-Ìý121
17.
Jackson ÌýSStorey ÌýAÌýE6 proteins from diverse cutaneous HPV types inhibit apoptosis in response to UV damage.ÌýÌýOncogene. 2000;19592-Ìý598
18.
Carter ÌýJJGalloway ÌýDAÌýHumoral immune response to human papillomavirus infection.ÌýÌýClin Dermatol. 1997;15249-Ìý259
19.
Baird ÌýPÌýSerological evidence for the association of papillomavirus and cervical neoplasia.ÌýÌýLancet. 1983;217-Ìý18
20.
Nonnenmacher ÌýBKruger-Kjaer ÌýSSvare ÌýEI Ìýet al.ÌýÌýSeroreactivity to HPV16 virus-like particles as a marker for cervical cancer risk in high-risk populations.ÌýÌýInt J Cancer. 1996;68704-Ìý709
21.
Wideroff ÌýLSchiffman ÌýMHHoover ÌýR Ìýet al.ÌýÌýEpidemiologic determinants of seroreactivity to human papillomavirus (HPV) type 16 virus-like particles in cervical HPV-16 DNA-positive and -negative women.ÌýÌýJ Infect Dis. 1996;174937-Ìý943
22.
Stark ÌýSPetridis ÌýAKGhim ÌýSJ Ìýet al.ÌýÌýPrevalence of antibodies against virus-like particles of epidermodysplasia verruciformis–associated HPV8 in patients at risk of skin cancer.ÌýÌýJ Invest Dermatol. 1998;111696-Ìý701
23.
Bouwes Bavinck ÌýJNStark ÌýSPetridis ÌýAK Ìýet al.ÌýÌýThe presence of antibodies against virus-like particles of epidermodysplasia verruciformis–associated human papillomavirus type 8 in patients with actinic keratoses.ÌýÌýBr J Dermatol. 2000;142103-Ìý109
24.
Wieland ÌýURitzkowsky ÌýAStoltidis ÌýM Ìýet al.ÌýÌýPapillomavirus DNA in basal cell carcinomas of immunocompetent patients.ÌýÌýJ Invest Dermatol. 2000;115124-Ìý128
25.
Kremsdorf ÌýDFavre ÌýMJablonska ÌýS Ìýet al.ÌýÌýMolecular cloning and characterization of the genomes of nine newly recognized human papillomavirus types associated with epidermodysplasia verruciformis.ÌýÌýJ Virol. 1984;521013-Ìý1018
26.
Kozak ÌýMÌýCompilation and analysis of sequences upstream from the translational start site in eukaryotic mRNAs.ÌýÌýNucleic Acids Res. 1984;12857-Ìý872
27.
Norusis ÌýMJÌýSPSS for Windows Professional and Advanced Statistics, Release 8.0.Ìý Chicago, Ill SPSS Inc1998;
28.
Stata Corp,ÌýStata Statistical Software: Release 4.0 for Windows 95.Ìý College Station, Tex Stata Corp1995;
29.
English ÌýDRArmstrong ÌýBKKricker ÌýAÌýReproducibility of reported measurements of sun exposure in a case-control study.ÌýÌýCancer Epidemiol Biomarkers Prev. 1998;7857-Ìý863
30.
Weinstock ÌýMAColditz ÌýGAWillett ÌýWCStampfer ÌýMJRosner ÌýBSpeizer ÌýFEÌýRecall (report) bias and reliability in the retrospective assessment of melanoma risk.ÌýÌýAm J Epidemiol. 1991;133240-Ìý245
31.
Cockburn ÌýMHamilton ÌýAMack ÌýTÌýRecall bias in self-reported melanoma risk factors.ÌýÌýAm J Epidemiol. 2001;1531021-Ìý1026
32.
Silins ÌýIWang ÌýZAvall-Lundqvist ÌýE Ìýet al.ÌýÌýSerological evidence for protection by human papillomavirus (HPV) type 6 infection against HPV type 16 cervical carcinogenesis.ÌýÌýJ Gen Virol. 1999;80 (pt 11) 2931-Ìý2936
33.
Schwartz ÌýSMDaling ÌýJRDoody ÌýDR Ìýet al.ÌýÌýOral cancer risk in relation to sexual history and evidence of human papillomavirus infection.ÌýÌýJ Natl Cancer Inst. 1998;901626-Ìý1636
34.
Favre ÌýMMajewski ÌýSNoszczyk ÌýB Ìýet al.ÌýÌýAntibodies to human papillomavirus type 5 are generated in epidermal repair processes.ÌýÌýJ Invest Dermatol. 2000;114403-Ìý407
35.
Tsambaos ÌýDMonastirli ÌýAKapranos ÌýN Ìýet al.ÌýÌýDetection of human papillomavirus DNA in nongenital seborrhoeic keratoses.ÌýÌýArch Dermatol Res. 1995;287612-Ìý615
36.
Yeatman ÌýJMKilkenny ÌýMMarks ÌýRÌýThe prevalence of seborrhoeic keratoses in an Australian population.ÌýÌýBr J Dermatol. 1997;137411-Ìý414
37.
Sciocchetti ÌýGClemente ÌýGFIngrao ÌýGSacco ÌýFÌýResults of a survey on radioactivity of building materials in Italy.ÌýÌýHealth Phys. 1983;45385-Ìý388
38.
Sperati ÌýAAbeni ÌýDDTagesson ÌýCForastiere ÌýFMiceli ÌýMAxelson ÌýOÌýExposure to indoor background radiation and urinary concentrations of 8-hydroxydeoxyguanosine, a marker of oxidative DNA damage.ÌýÌýEnviron Health Perspect. 1999;107213-Ìý215
39.
Etherington ÌýDJPheby ÌýDFBray ÌýFIÌýAn ecological study of cancer incidence and radon levels in South West England.ÌýÌýEur J Cancer. 1996;32A1189-Ìý1197
40.
Eatough ÌýJPHenshaw ÌýDLÌýThe theoretical risk of non-melanoma skin cancer from environmental radon exposure.ÌýÌýJ Radiol Prot. 1995;1545-Ìý51
×